Serum YKL-40 levels in patients with multiple sclerosis

dc.authorid0000-0003-0527-189Xen_US
dc.authorid0000-0003-1753-1046en_US
dc.contributor.authorDönder, Ahmet
dc.contributor.authorÖzdemir, Hasan Hüseyin
dc.date.accessioned2021-10-26T13:44:53Z
dc.date.available2021-10-26T13:44:53Z
dc.date.issued2021en_US
dc.departmentMAÜ, Meslek Yüksekokulları, Sağlık Hizmetleri Meslek Yüksekokulu, Tıbbi Hizmetler ve Teknikler Bölümüen_US
dc.description.abstractBackground: Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system. The YKL-40 protein, which is secreted from various cells that contribute to inflammation and infection, plays a role in immune regulation. Objective: This study investigated the serum YKL-40 levels of patients with clinically isolated syndrome (CIS) and MS. Methods: The participants was divided into three groups: 1) patients with CIS (n = 20); 2) patients with relapsing-remitting MS (RRMS; n = 39); and 3) healthy individuals (n = 35). The YKL-40 levels in serum samples obtained from the participants were measured using enzyme-linked immunoassays. Results: The median serum YKL-40 level was 20.2 ng/mL (range 9.8-75.9 ng/mL) in the patients with CIS, 22.7 ng/mL (range 13.4-57.9 ng/mL) in the patients with RRMS and 11.0 ng/mL (range 10.0-17.3 ng/mL) in the control group (p < 0.001). The serum YKL-40 levels in the patients with RRMS were correlated with the patients’ expanded disability status scale scores and ages (p < 0.05). No relationships were determined between the serum YKL-40 levels and the other variables (p > 0.05). The serum YKL-40 levels were higher in the CIS group than in the MS group. These findings show that the serum YKL-40 levels were high even at the beginning of the disease. The serum YKL-40 levels were also not involved in the progression to clinically definite MS. Conclusions: The findings from this study suggested that YKL-40 may be a useful marker for the inflammatory process of MS.en_US
dc.identifier.citationDönder, A., Özdemir, H. H. (2021). Serum YKL-40 levels in patients with multiple sclerosis. Arq Neuropsiquiatr. 79(9). s.795-798. https://doi.org/10.1590/0004-282X-ANP-2020-0326en_US
dc.identifier.doi10.1590/0004-282X-ANP-2020-0326en_US
dc.identifier.endpage798en_US
dc.identifier.issue9en_US
dc.identifier.pmid34669813en_US
dc.identifier.scopus2-s2.0-85117422218en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage795en_US
dc.identifier.urihttps://doi.org/10.1590/0004-282X-ANP-2020-0326
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/34669813/
dc.identifier.urihttps://hdl.handle.net/20.500.12514/2912
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000727387000007?AlertId=d383397b-4355-449e-9419-70f9e0e77c15&SID=C5SgKDSVhSewUW1fy8w
dc.identifier.urihttps://www.scopus.com/record/display.uri?eid=2-s2.0-85117422218&origin=resultslist&sort=plf-f&src=s&st1=10.1590%2f0004-282X-ANP-2020-0326&sid=64b47c7915e5aef88108233229454690&sot=b&sdt=b&sl=36&s=DOI%2810.1590%2f0004-282X-ANP-2020-0326%29&relpos=0&citeCnt=0&searchTerm=
dc.identifier.volume79en_US
dc.identifier.wosWOS:000727387000007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherArq Neuropsiquiatren_US
dc.relation.ispartofArq Neuropsiquiatren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMultiple Sclerosis; Demyelinating Diseases; Multiple Sclerosis, Relapsing-Remitting; Chitinase-3-Like Protein 1en_US
dc.titleSerum YKL-40 levels in patients with multiple sclerosisen_US
dc.title.alternativeNíveis séricos de YKL-40 em pacientes com esclerose múltiplaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
indir.pdf
Boyut:
107.82 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text - Article
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: